NCT04541550View on ClinicalTrials.gov

Allogeneic Micronized Amniotic Membrane Product for the Treatment of Hidradenitis Suppurativa

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 1, 2021

Primary Completion Date

July 1, 2021

Study Completion Date

July 1, 2021

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

AMP-001 Low Dose

AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.

DRUG

AMP-001 Medium Dose

AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.

DRUG

AMP-001 High Dose

AMP-001, is manufactured from the amniotic membrane of the placenta and does not contain living cells.

Trial Locations (1)

77082

West Houston Dermatology Laser and Skin Care Center, Houston

Sponsors

Lead Sponsor

IntegoGen, LLC
All Listed Sponsors
lead

IntegoGen, LLC

INDUSTRY